local_hospital

Framol-Med GmbH

Address
lock Available on a paid plan

Respiratory Tract Diseases

At Framol-Med GmbH, the clinical research focus is centered on Respiratory Tract Diseases, with studies exploring both asthma and chronic obstructive pulmonary disease. The trials are designed to assess how well new and existing inhaled and biologic treatments can improve symptom control, reduce flare-ups, and support better long-term lung health.

  • Evaluating combination inhaler therapies for better control of chronic breathing disorders
  • Studying treatments aimed at reducing COPD exacerbations and related complications
  • Assessing new options for asthma management in adolescents and adults

This research includes efforts to compare treatment effectiveness against standard care or placebo, helping clarify which approaches may offer the greatest benefit for patients with moderate-to-severe COPD and related respiratory conditions.

Chronic Obstructive Pulmonary Disease

The Pulmonology department at this hospital is conducting multiple trials focused on COPD, including more advanced forms of the disease. These studies are examining therapies intended to reduce worsening episodes, improve breathing outcomes, and address the needs of people living with persistent airway inflammation.

  • Testing whether biologic therapies can lower the frequency of COPD attacks
  • Comparing treatment strategies to improve cardiopulmonary outcomes
  • Exploring new approaches for patients with type 2 inflammation and chronic airway disease

The overall goal is to generate clearer evidence on how emerging therapies may help patients with moderate-to-severe COPD achieve better disease control and quality of life.

Asthma

Research at Framol-Med GmbH also includes asthma, with trials looking at the effectiveness and safety of combination inhaled therapy. These studies aim to improve everyday symptom management and provide better options for people whose asthma remains difficult to control.

  • Evaluating inhaled combination treatments for symptom relief and disease control
  • Comparing active therapy with placebo to measure treatment benefit
  • Supporting better care for adolescents and adults with persistent asthma

This area of research is focused on understanding whether newer treatment combinations can offer more effective control than current approaches while maintaining safety in routine respiratory care.

Site Overview

assignment
6
connected trials
corporate_fare
6
sponsors
science
10
IMPs

Activity Indicator

Last 6 months

1
Trials started
0% vs previous period.
1
Trials started 6–12 months ago
6
Total trials linked
Active
trending_flatStable0%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
3
Sponsors (total)
6
Active sponsors
3

Sponsor Network

Top 3 by active trials.

lock +2 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
6
Outperforms 75% of sites
public
Therapeutic diversity
1areas
Outperforms 2% of sites
groups
Sponsor diversity
6sponsors
Outperforms 78% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Framol-Med GmbH

lock Showing 1 of 6 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 10 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Salbutamol Sulfate2Unknown2025-07-222026-05-19

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.